Skip to main content
Retour
ABCL logo

AbCellera Biologics Inc.

Qualité des données : 100%
ABCL
NASDAQ Healthcare Biotechnology
3,31 €
▼ 0,05 € (-1,49%)
Cap. Boursière : 1,00B
Fourchette du Jour
3,27 € 3,35 €
Fourchette 52 Semaines
1,89 € 6,52 €
Volume
2 045 398
Moyenne 50J / 200J
3,62 € / 4,10 €
Clôture Précédente
3,36 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -6,9 0,3
P/B 0,9 2,9
ROE % -13,3 3,7
Net Margin % -194,9 3,8
Rev Growth 5Y % -33,1 10,0
D/E 0,1 0,2

Objectif de Cours des Analystes

Hold
20,17 € +509.4%
Low: 5,00 € High: 34,00 €
BPA Prévisionnel
-0,65 €
CA Est.
30 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 -0,59 €
-1,17 € – -0,34 €
120 M 1
FY2029 -0,75 €
-1,48 € – -0,42 €
72 M 1
FY2028 -0,78 €
-0,85 € – -0,65 €
55 M 3

Points Clés

Revenue declined -33,11% annually over 5 years
Debt/Equity of 0,13 — conservative balance sheet
Negative free cash flow of -174,07M
PEG of 0,64 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 193,67%
Capital intensive — 56,93% of revenue goes to capex

Croissance

Revenue Growth (5Y)
-33,11%
Revenue (1Y)160,56%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-13,33%
ROIC-12,68%
Net Margin-194,88%
Op. Margin-288,98%

Sécurité

Debt / Equity
0,13
Current Ratio11,32
Interest Coverage0,00

Valorisation

P/E Ratio
-6,85
P/B Ratio0,88
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 160,56% Revenue Growth (3Y) 40,56%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -33,11% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 75,13M Net Income (TTM) -146,41M
ROE -13,33% ROA -10,79%
Gross Margin 100,00% Operating Margin -288,98%
Net Margin -194,88% Free Cash Flow (TTM) -174,07M
ROIC -12,68% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,13 Current Ratio 11,32
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -6,85 P/B Ratio 0,88
P/S Ratio 13,36 PEG Ratio 0,64
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,00B Enterprise Value 991,66M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 75,13M 28,83M 38,03M 485,42M 375,20M
Net Income -146,41M -162,86M -146,40M 158,52M 153,46M
EPS (Diluted) -0,49 -0,55 -0,51 0,50 0,48
Gross Profit 75,13M 28,83M 38,03M 418,99M 329,69M
Operating Income -217,10M -314,77M -237,21M 216,51M 204,41M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,36B 1,36B 1,49B 1,54B 1,32B
Total Liabilities 215,59M 304,47M 335,78M 307,63M 292,84M
Shareholders' Equity 1,14B 1,06B 1,15B 1,23B 1,03B
Total Debt 143,22M 65,36M 77,38M 82,26M 40,07M
Cash & Equivalents 155,01M 156,33M 133,32M 386,54M 476,14M
Current Assets 728,23M 751,37M 871,99M 1,03B 929,80M
Current Liabilities 64,31M 76,61M 119,01M 118,32M 120,68M